Friday, February 09, 2007
Prescription Drugs, Waste, Fraud, and Abuse
Prescription Drugs, Waste, Fraud, and Abuse
Financial Impacts of Waste, Fraud, and Abuse in Pharmaceutical Pricing
The goal of the hearing is to examine whether there are fraudulent, abusive, or wasteful pharmaceutical pricing practices that affect federal health programs such as Medicaid, Medicare, and the Public Health Service “340B” program that should be the subject of additional congressional oversight. A preliminary transcript of this hearing is now available.
Video of the hearing:
Documents and Links
Opening Statement of Chairman Henry A. Waxman (64 KB)- GAO Report: Prescription Drugs: Oversight of Drug Pricing in Federal Programs (229 KB)
- Testimony of Lewis Morris (59 KB)
- Testimony of Patrick J. O'Connell (28 KB)
- Testimony of James W. Moorman (178 KB)
- Testimony of Ronald J. Tenpas (116 KB)
- Testimony of Gerard F. Anderson (118 KB)
- Preliminary Hearing Transcript (6 MB)
